Kefah Mokbel, Chair of Breast Cancer Surgery at London Breast Institute and Honorary Professor of Medicine at Cardiff University School of Medicine, shared a post on LinkedIn:
“The new findings on SU212 are clinically promising. By targeting alpha-enolase (ENO1) to disrupt tumor metabolism while also improving systemic metabolic dysfunction, SU212 offers a rare dual-action approach that could benefit patients with aggressive cancers such as TNBC, particularly those with metabolic comorbidities.
If confirmed in clinical studies, SU212 could help reshape metabolism-directed cancer therapy by delivering both anticancer activity and metabolic improvement.”
Title: Non-orthosteric inhibition of enolase 1 impedes growth of triple-negative breast cancer
Authors: Dhanir Tailor, Fernando Jose Garcia-Marques, Abel Bermudez, Annah S. Rolig, Benedikt Grau, Arpit Dheeraj, Dhanya K. Nambiar, Wenqi Li, Kirsten Stefan, Shawn Campbell, Sharon J. Pitteri, Sanjay V. Malhotra
Read the Full Article.
More posts featuring Kefah Mokbel on OncoDaily.